| |
| |
|
| Insider
Information: |
Altshuler David |
| Relationship: |
EVP, Chief Scientific... |
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
25,813 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$11,436,450 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
25,813 |
|
|
| Total
Value |
$11,436,450 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Vertex Pharmaceuticals Inc |
VRTX |
EVP, Chief Scientific... |
2024-05-15 |
25,813 |
2014-07-31 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
157 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 4 of 7
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2018-08-28 |
4 |
AS |
$181.89 |
$386,516 |
D/D |
(2,125) |
39,113 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2018-11-07 |
4 |
AS |
$181.89 |
$386,516 |
D/D |
(2,125) |
39,113 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2022-11-07 |
4 |
AS |
$299.72 |
$394,859 |
D/D |
(1,303) |
36,077 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2023-02-06 |
4 |
AS |
$300.39 |
$399,022 |
D/D |
(1,304) |
68,645 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2018-11-05 |
4 |
AS |
$172.08 |
$400,946 |
D/D |
(2,330) |
39,113 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2022-02-02 |
4 |
OE |
$86.52 |
$403,183 |
D/D |
4,660 |
70,357 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2018-08-03 |
4 |
AS |
$174.20 |
$405,886 |
D/D |
(2,330) |
39,113 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-01-22 |
4 |
AS |
$193.48 |
$411,145 |
D/D |
(2,125) |
39,113 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
Director |
– • – |
2014-11-28 |
4 |
AS |
$119.75 |
$419,125 |
D/D |
(3,500) |
0 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-02-06 |
4 |
OE |
$155.57 |
$434,614 |
D/D |
2,526 |
72,836 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2017-04-28 |
4 |
OE |
$63.14 |
$473,550 |
D/D |
7,500 |
113,511 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2018-10-01 |
4 |
AS |
$194.62 |
$475,846 |
D/D |
(2,445) |
39,113 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
Director |
– • – |
2014-09-19 |
4 |
AS |
$99.75 |
$511,250 |
D/D |
(5,000) |
0 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2021-02-24 |
4 |
D |
$217.57 |
$525,649 |
D/D |
(2,416) |
36,617 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2022-02-11 |
4 |
AS |
$233.92 |
$539,837 |
D/D |
(2,297) |
59,882 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2017-06-05 |
4 |
OE |
$72.14 |
$541,050 |
D/D |
7,500 |
113,511 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2017-02-13 |
4 |
AS |
$87.68 |
$561,415 |
D/D |
(6,403) |
106,011 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2022-02-14 |
4 |
AS |
$232.02 |
$567,057 |
D/D |
(2,444) |
57,438 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-10-22 |
4 |
OE |
$155.57 |
$570,786 |
D/D |
3,669 |
35,222 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-02-24 |
4 |
D |
$239.23 |
$577,980 |
D/D |
(2,416) |
31,930 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-02-17 |
4 |
D |
$241.50 |
$602,784 |
D/D |
(2,496) |
37,474 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-02-06 |
4 |
AS |
$238.74 |
$604,775 |
D/D |
(2,526) |
70,310 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-05-04 |
4 |
AS |
$259.18 |
$607,803 |
D/D |
(2,330) |
28,902 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2021-02-10 |
4 |
D |
$214.16 |
$636,912 |
D/D |
(2,974) |
58,381 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2021-02-25 |
4 |
AS |
$211.58 |
$646,139 |
D/D |
(3,028) |
33,589 |
0 |
% |
|
157 Records found
|
|
Page 4 of 7 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
